Fractyl Health Investor Relations Material

Fractyl Health Inc. is a healthcare biotechnology company dedicated to the development of innovative therapies for metabolic diseases, particularly type 2 diabetes (T2D) and obesity. The company's main therapeutic platforms include Revita DMR and Rejuva. Revita DMR is an outpatient procedural therapy aimed at modifying duodenal dysfunction—a condition influenced by a high-fat and high-sugar diet which can lead to T2D and obesity. Rejuva represents a novel gene therapy platform, delivered via adeno-associated virus, designed to achieve long-term remission of T2D and obesity by altering metabolic hormone function in pancreatic islet cells. The company is headquartered in Burlington, Massachusetts, and its shares are listed on the NASDAQ.